Not available
Quote | MEI Pharma Inc. (NASDAQ:MEIP)
Last: | $3.10 |
---|---|
Change Percent: | 0.0% |
Open: | $3.26 |
Close: | $3.10 |
High: | $3.26 |
Low: | $3.1 |
Volume: | 16,736 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | MEI Pharma Inc. (NASDAQ:MEIP)
2024-04-11 14:17:44 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma Financial information for MEI Pharma Read the full article on Seeking Alpha For further details see: MEI Pharma she...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
Message Board Posts | MEI Pharma Inc. (NASDAQ:MEIP)
Subject | By | Source | When |
---|---|---|---|
Out. May recover but R/S concern is | kzivann | investorshub | 12/06/2022 2:46:15 PM |
Doing a little. Risking a part of | kzivann | investorshub | 12/06/2022 12:56:43 PM |
Whats your take on Today thinking if loading | INFINITI | investorshub | 12/06/2022 12:53:43 PM |
Lead drug. FDA issue. Continuing trails in | kzivann | investorshub | 12/06/2022 12:48:06 PM |
Why did it drop so much | INFINITI | investorshub | 12/06/2022 12:42:39 PM |
News, Short Squeeze, Breakout and More Instantly...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a firesi...